Verve Ventures

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Neo Medical SA is a medical technology company based in Villette, Switzerland, with additional offices in Germany, France, and the United States. Founded in 2013, the company specializes in developing, manufacturing, and commercializing non-constraint thoraco-lumbar spinal fusion systems for spinal surgery. Its flagship product, the Neo Pedicle Screw System, offers a range of functionalities such as reduction, compression, distraction, and screw augmentation, addressing various pathologies including degenerative conditions, tumors, and trauma. Neo Medical aims to enhance the efficiency of healthcare delivery by providing versatile and high-quality surgical solutions, thereby contributing to the ongoing pursuit of healthcare cost optimization.

Limula develops an automated cell therapy manufacturing platform that combines bioreactor and centrifuge capabilities into a single device, supported by hardware, software, and consumables. The platform enables scalable, decentralized production of cell therapies by bringing manufacturing closer to patients and supporting multiple cell types. It automates complex processing steps within a closed, modular system, allowing biotech and pharmaceutical companies to move from open, manual methods to automated operations, improving efficiency, safety, and accessibility of personalized treatments.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Artiria Medical develops innovative guidewire systems designed to enhance navigation during neurovascular procedures. Its products feature dynamic tip deflection, superior torque transmission, a high-quality hydrophilic coating, smooth intravascular navigation, adjustability, and a controlled tip deflection mechanism. These devices aim to facilitate complex interventions, reduce procedure-related risks, and improve overall efficiency.

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.

Hylomorph is a MedTech company that develops biomaterial solutions to improve the interface between implantable medical devices and biological tissue. Its technology includes a cellulose film designed to prevent fibrotic encapsulation and adhesion, helping to reduce postoperative complications such as fibrosis, infection, and device migration, thereby aiming to lower implant failure. The approach combines biotech with surface micro-engineering to optimize tissue implant interaction. First indications target cardiac devices like pacemakers and defibrillators, as well as neurostimulators. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

German Version below: marta offers a market place for families, people in need of care and European caregivers. We believe that, on the one hand everyone has the right to receive appropriate care and to age with dignity and on the other hand caregivers should be able to do their work under fair conditions. We are working on software solutions to connect caregivers with families across Europe and we support both parties during the entire process. In our own families we have seen that the current market is characterized by non-transparent services and does not deliver adequate quality. It is out mission to change that. That is why we at marta pursue the goal of making things better by applying our software solutions to fundamentally rebuilding the "24-hour" care market. Deutsche Version: marta bietet einen Marketplatz für Familien, pflegebedürftige Menschen und europäische Pflegekräfte. Aus unserer Sicht, hat zum einen jede/r das Recht darauf, angemessene Pflege zu erhalten und in Würde zu altern und zum anderen sollten Pflegekräfte unter fairen Bedingungen ihre Arbeit machen können. Wir arbeiten an dem Bau von Softwarelösungen, um Pflegekräfte mit Familien in ganz Europa zu verbinden und während der Betreuung zu begleiten. In unseren eigenen Familien haben wir gesehen, dass der derzeitige Markt von intransparenten Dienstleistungen geprägt ist und keine angemessene Qualität liefert. Deswegen verfolgen wir bei marta das Ziel, es durch unsere Softwarelösungen besser zu machen und den Markt der "24-Stunden" Pflege grundlegend neu aufzubauen.

Piomic Medical develops a non-invasive, portable handheld device to treat chronic wounds, particularly hard-to-heal leg and foot ulcers. The COMS One Therapy System combines optical and magnetic stimulation to promote wound healing, with clinical data indicating safe use, accelerated wound closure, reduced pain, and improved quality of life. The device is lightweight and user-friendly, designed for use in clinics, ambulatory settings, and home care, enabling patients to continue treatment outside traditional facilities. By offering a safe and effective non-invasive therapy, Piomic Medical aims to alleviate the burden of chronic wounds on patients and healthcare systems.

Therapixel develops and commercializes AI-based medical imaging software for surgeons, focusing on breast cancer detection and characterization and intraoperative image management. The company designs image analytics tools that enable clinicians to access and interpret medical images before or during procedures while maintaining sterility through touchless interfaces. Its product family includes Radvise, an automatic image reading solution; Fluid, a touchless medical image navigation system for surgery; Anywhere, a post-processing workstation; and CD-Feed, a CD import solution for outpatient imaging exams. Founded in 2013 and headquartered in Valbonne, France, Therapixel operates globally with a presence in multiple countries, supporting surgeons with timely, decision-ready imaging information.

Founded in Zurich, Switzerland in 2018, Sleepiz develops a non-contact multidimensional sleep monitoring device. It tracks breathing, heart rate, and body movements with medical-grade accuracy, enabling diagnosis of sleep disorders and long-term patient-centric disease management.

Founded in 2018, 9T Labs specializes in manufacturing advanced 3D printers that produce carbon composites. Their proprietary technology combines software, additive manufacturing, and industry-standard materials to deliver digital composite production solutions. This enables manufacturers to create lighter structural parts with true 3D fiber orientation at a lower cost.

Nanoleq develops and manufactures electric cables using stretchable electronics, serving sectors such as healthcare, robotics, aerospace, and electronics. Its products include shields and conductors for various applications.

Hylomorph is a MedTech company that develops biomaterial solutions to improve the interface between implantable medical devices and biological tissue. Its technology includes a cellulose film designed to prevent fibrotic encapsulation and adhesion, helping to reduce postoperative complications such as fibrosis, infection, and device migration, thereby aiming to lower implant failure. The approach combines biotech with surface micro-engineering to optimize tissue implant interaction. First indications target cardiac devices like pacemakers and defibrillators, as well as neurostimulators. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

Medimaps Group develops medical software that enhances osteoporosis diagnosis by assessing bone microarchitecture. Its AI-driven imaging tools help clinicians select appropriate treatments and monitor outcomes, with future applications in dental and orthopedic fields.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

Founded in 2017, Scewo designs and manufactures innovative electric wheelchairs for individuals with mobility impairments. Its flagship product is a stair-climbing wheelchair that combines wheels and tracks with an active control system, enabling users to navigate various terrains and obstacles.

Founded in Zurich, Switzerland in 2018, Sleepiz develops a non-contact multidimensional sleep monitoring device. It tracks breathing, heart rate, and body movements with medical-grade accuracy, enabling diagnosis of sleep disorders and long-term patient-centric disease management.

Sympatient develops virtual reality-based psychotherapy treatments for anxiety disorders. It offers apps like Otemi for stress management and Invirto for independent anxiety therapy at home. The company combines digital therapeutics with therapist sessions, providing accessible personalized mental health care.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.

Artiria Medical develops innovative guidewire systems designed to enhance navigation during neurovascular procedures. Its products feature dynamic tip deflection, superior torque transmission, a high-quality hydrophilic coating, smooth intravascular navigation, adjustability, and a controlled tip deflection mechanism. These devices aim to facilitate complex interventions, reduce procedure-related risks, and improve overall efficiency.

Sympatient develops virtual reality-based psychotherapy treatments for anxiety disorders. It offers apps like Otemi for stress management and Invirto for independent anxiety therapy at home. The company combines digital therapeutics with therapist sessions, providing accessible personalized mental health care.

Neo Medical SA is a medical technology company based in Villette, Switzerland, with additional offices in Germany, France, and the United States. Founded in 2013, the company specializes in developing, manufacturing, and commercializing non-constraint thoraco-lumbar spinal fusion systems for spinal surgery. Its flagship product, the Neo Pedicle Screw System, offers a range of functionalities such as reduction, compression, distraction, and screw augmentation, addressing various pathologies including degenerative conditions, tumors, and trauma. Neo Medical aims to enhance the efficiency of healthcare delivery by providing versatile and high-quality surgical solutions, thereby contributing to the ongoing pursuit of healthcare cost optimization.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

Founded in 2018, 9T Labs specializes in manufacturing advanced 3D printers that produce carbon composites. Their proprietary technology combines software, additive manufacturing, and industry-standard materials to deliver digital composite production solutions. This enables manufacturers to create lighter structural parts with true 3D fiber orientation at a lower cost.

Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is a medical device company focused on developing innovative delivery systems for biologic substances. The company has designed a device that is encapsulated in a standard-sized capsule, utilizing injection molding technology. This device eliminates mechanical moving components and harnesses the body's natural peristaltic forces to facilitate the effective and painless delivery of medications directly into the gastrointestinal wall. By replacing traditional injection methods, Biograil aims to enhance patient comfort and improve the administration of medications.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral therapies. The device delivers self-controlled stimulation to the cavernous nerve via a wireless remote, aiming to restore natural function and provide a safe, effective alternative that can improve quality of life for men with erectile dysfunction.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Luciole Medical AG is a Swiss medical technology company that specializes in the design and manufacture of brain oxygenation monitoring systems. Founded in 2017 and based in Zurich, the company has developed a platform that accurately measures the levels of oxygenated and deoxygenated hemoglobin, as well as cerebral blood flow and other critical parameters. Its product lineup includes RheoPatch, a non-invasive sensor applied to the skin to assess oxygen metabolism and blood flow; RheoSens, an implantable probe that measures various cerebral metrics; RheoLity, which offers software for data display, analysis, and patient management; and RheoControl, which connects to medical monitors for data visualization. Luciole Medical's systems enable healthcare professionals to monitor cerebral oxygenation effectively, providing crucial insights into the patient's brain health.

Hylomorph is a MedTech company that develops biomaterial solutions to improve the interface between implantable medical devices and biological tissue. Its technology includes a cellulose film designed to prevent fibrotic encapsulation and adhesion, helping to reduce postoperative complications such as fibrosis, infection, and device migration, thereby aiming to lower implant failure. The approach combines biotech with surface micro-engineering to optimize tissue implant interaction. First indications target cardiac devices like pacemakers and defibrillators, as well as neurostimulators. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

Abionic develops innovative nanotechnology-based diagnostic solutions. Its flagship product, abioSCOPE, enables rapid allergy profiling from a single drop of blood, improving medical diagnosis at clinical labs and point-of-care settings.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Medyria is a Swiss medtech company developing sensor-based catheter navigation and sensing systems for vascular, valve, and heart procedures. Its products include a sensor-based catheter positioning system for X-ray- and dye-free minimally invasive cardiovascular procedures, Flowcath for measuring blood flow, Trackcath for processing flow data and tracking catheters, and an OEM flow sensor for measuring blood or physiological fluid flow. The company uses proprietary Blood Flow Velocity Sensor technology to enable safer and more effective endovascular procedures by reducing procedural manipulations, duration, complications, and overall costs. Medyria is based in Winterthur, Switzerland.

DBS System SA is a medtech company based in the Swiss Health Valley that specializes in the production of HemaXis™ blood collection devices. The company utilizes advanced microfluidic technology to create innovative devices designed for the less invasive, safer, and more efficient collection and preparation of blood samples. HemaXis devices facilitate plasma and serum extraction with precision and in a standardized format, significantly enhancing the capabilities of dried blood spot samples in bioanalysis. By streamlining blood collection processes, DBS System aims to support health monitoring and testing while contributing to the advancement of personalized medicine and big data initiatives.

Medyria is a Swiss medtech company developing sensor-based catheter navigation and sensing systems for vascular, valve, and heart procedures. Its products include a sensor-based catheter positioning system for X-ray- and dye-free minimally invasive cardiovascular procedures, Flowcath for measuring blood flow, Trackcath for processing flow data and tracking catheters, and an OEM flow sensor for measuring blood or physiological fluid flow. The company uses proprietary Blood Flow Velocity Sensor technology to enable safer and more effective endovascular procedures by reducing procedural manipulations, duration, complications, and overall costs. Medyria is based in Winterthur, Switzerland.

Tecuro is a Switzerland-based medical technology company headquartered in Gerliswil, Luzern, focused on preventing urinary tract infections. It has developed an antimicrobial, skin-friendly platform delivered via external application, with the U-med Pad as a near-market-ready product to prevent urinary tract diseases, especially in women's urology. The platform enables non-systemic protection against UTIs and uro-vaginal infections and aims to counter antibiotic resistance through topical use. The technology is protected by patents, offering a long-term competitive edge and potential for additional products built on the same platform. Tecuro has completed the steps needed for series-compatible production, positioning itself to scale its external-application approach to reducing recurrent UTIs for women.

MEDUDEM Corp. is a company in the digital health sector that focuses on the improvement of collaboration and interaction of all participants involved around chronic diseases (CCM). On the basis of its readily available web- and mobile-based solutions Care Integrator® and Healthbrain®, MEDUDEM Corp. improves collaboration and exchanges between medical professionals and patients, as well as third-party organizations. This provides clear advantages and synergetic benefits for all parties in and around the healthcare market and ensures the interaction and communication in a simple, fast and comprehensive way and manner.

Founded in 2009, Qvanteq is a Swiss medtech company specializing in the development of innovative bioactive stents. Its flagship product, Qstent, addresses and mitigates clinical adverse effects of coronary and endovascular stents by controlling in-growth and reducing restenosis risk.